Aerpio Comes to the 'Rescue' With HPTP-beta Drug for DME

Flush with $27 million from a Series A in August, Aerpio Therapeutics Inc. is moving full speed ahead into its clinical development program for AKB-9778, a first-in-class human protein tyrosine phosphatase-beta (HPTP-beta) inhibitor, with dosing of the first patients in a Phase Ib/IIa study in diabetic macular edema (DME).